Congress moves to end tobacco tax loopholes, raising rates across all products
H.R. 1798 — End Tobacco Loopholes Act · Filed by Raja Krishnamoorthi (D-IL) · 3 cosponsors · Introduced Mar 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill raises federal excise taxes on tobacco and nicotine products to create tax parity across different forms—cigarettes, cigars, smokeless tobacco, pipe tobacco, roll-your-own tobacco, and newly extracted/synthesized nicotine used in vaping. It increases cigarette taxes substantially (small cigarettes to $100.66 per thousand, large to $211.38 per thousand), applies new taxes to nicotine concentrates at $49.56 per 1,810 milligrams, and indexes all rates to inflation annually starting in 2026. The bill exempts FDA-approved nicotine drugs and includes a floor-stocks tax on inventory held when rates increase, with a $500 per-person credit.
Why we flagged it
The bill's core function is to align excise tax rates across all tobacco and nicotine products to eliminate tax-driven product substitution and raise revenue for public health. It is straightforward tax policy with a clear public-health objective, not a hidden carve-out or subsidy.
What the text implies
- The new tax on extracted/synthesized nicotine may accelerate the shift toward FDA-approved nicotine replacement therapies (NRTs), potentially benefiting pharmaceutical companies producing approved cessation products while raising costs for vaping manufacturers.
- Floor-stocks tax with $500 per-person credit creates a one-time revenue spike but may incentivize rapid inventory liquidation and temporary price spikes at retail, affecting low-income smokers disproportionately in the transition period.
- Inflation indexing (starting 2026) locks in automatic tax increases without future congressional votes, shifting tobacco tax policy from legislative to administrative control and reducing transparency of future rate changes.
- The definition of 'discrete single-use units' (lozenges, pouches, strips) at $100.66 per thousand may inadvertently capture emerging nicotine products not yet on market, creating regulatory uncertainty for innovation in harm-reduction products.
Who it affects
Ordinary citizens benefit through reduced smoking rates (higher taxes deter consumption, especially among price-sensitive youth and lower-income smokers), increased public health revenue for cessation programs, and elimination of tax arbitrage that currently incentivizes switching to less-regulated products. The primary cost falls on smokers and tobacco companies, not the general public.
Who stands to gain
- pharmaceutical companies (FDA-approved nicotine replacement therapies)
- state and local governments (increased tobacco tax revenue)
- public health organizations (cessation program funding)
Named in the bill
Internal Revenue Code Section 5701, Internal Revenue Code Section 5702, FDA (Food and Drug Administration), HHS (Department of Health and Human Services), Philip Morris (PM), Altria (MO), British American Tobacco (BTI), Imperial Brands (IMBBF), Turning Point Brands (TPB), 22nd Century Group (XXII), Tobacco manufacturers, Vaping/e-cigarette manufacturers — and 1 more
Where it stands
3 cosponsors: 3 Democrats.
- Mar 3, 2025 — Introduced · Congress.gov: “Introduced in House”
- Mar 3, 2025 — Referred to House Committee on Ways and Means · Congress.gov: “Referred to the House Committee on Ways and Means”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
3 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $6,710,000 in lobbying spend. A filing names 11 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 61% of bills with at least one filing.
Raja Krishnamoorthi, the sponsor, reported $763,350 in PAC receipts in the 2026 cycle.
- Altria Client Services LLC — $6,490,000 on 2 filings
- Japan Tobacco International U.s.a., Inc. — $220,000 on 1 filing
- Americans for Nonsmokers' Rights — $0 on 2 filings
Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 2, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 21, 2026 · page rendered 2026-10-20.
“Congress moves to end tobacco tax loopholes, raising rates across all products” QuorumCivic. https://share.quorumcivic.app/bill/119/hr1798 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.